Publications by authors named "Herrmann Joerg"

Claim this Profile
C
Characterization of Cardiovascular Events and Prognosis in Immune Checkpoint Inhibitor-Related Myocarditis.
Milagros Pereyra Pietri, Juan M Farina, Isabel G Scalia, Michael Roarke, Ahmed K Mahmoud, Joerg Herrmann

Mayo Clin Proc· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radionuclide imaging in cardio-oncology: A clinical decision-making tool.
Teodora Donisan, Daniel Sykora, Dinu V Balanescu, Ian C Chang, Grace Lin, Joerg Herrmann

Prog Cardiovasc Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilization and Outcomes of Structural Heart Disease Interventions in Patients With Prior Mediastinal Radiation.
Mahmoud Ismayl, Hasaan Ahmed, Andrew M Goldsweig, Joerg Herrmann, Mackram F Eleid

JACC Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular Toxicities of Cancer Therapies: 2025 Update.
Teodora Donisan, Dinu V Balanescu, Jun-Ichi Abe, Amir Lerman, Cezar A Iliescu, Joerg Herrmann

Arterioscler Thromb Vasc Biol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A simplified bedside model for prediction of acute kidney injury after percutaneous coronary intervention: CRASH score.
Dinu V Balanescu, Kaniz Fatema, Brad R Lewis, Patricia J M Best, Rajiv Gulati, Joerg Herrmann

J Cardiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement.
Joerg Herrmann, Ana Barac, Joseph Carver, Richard K Cheng, Andres Daniele

JAMA Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Free fall: Cardiometabolic disturbances, cancer and its treatment.
Jordan C Ray, Joerg Herrmann

Trends Cardiovasc Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic and Prognostic Value of High-Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy.
Milagros Pereyra Pietri, Juan M Farina, Kamal Awad, Christopher N Kanaan, Isabel G Scalia, Joerg Herrmann

J Am Heart Assoc· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SHP2: A Redox-Sensitive Regulator Linking Immune Checkpoint Inhibitor Therapy to Cancer Treatment and Vascular Risk.
Silvia Fernanda López Moreno, Stefania Assunto Lenz, Bernardo Casso-Chapa, Angelica Paniagua-Bojorges, Jung Hyun Kim, Joerg Herrmann

Antioxidants (Basel)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of Creatinine and Cystatin C-Based Equations to Estimate Glomerular Filtration Rate Among Patients With Heart Failure.
John Roth, John C Lieske, Sandra M Herrmann, A M Arruda-Olson, Joerg Herrmann

Circ Heart Fail· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Tolerance to Anthracycline Chemotherapy Using Electrocardiogram-Based Artificial Intelligence in Sarcoma.
Jack B Korleski, Regina M Koch, Thanh P Ho, Steven I Robinson, Scott H Okuno, Joerg Herrmann

Mayo Clin Proc Digit Health· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Itaconate promotes inflammatory responses in tissue-resident alveolar macrophages and exacerbates acute lung injury.
Mengtian Shan, Song Zhang, Zhibing Luo, Shengjie Deng, Linyu Ran, Joerg Herrmann

Cell Metab· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitor myocarditis-a score to tell you more.
Joerg Herrmann, Alexander R Lyon

Eur Heart J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Outcomes of Atrial Arrhythmia with CDK4/6 Inhibitors in HR-Positive / HER2-Negative Breast Cancer.
Nathaniel E Davis, Joerg Herrmann, David O Hodge, Sophia Blumenfeld, Kathryn J Ruddy

medRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impacts of Radiation on Metabolism and Vascular Cell Senescence.
Junichi Abe, Khanh Chau, Anahita Mojiri, Guangyu Wang, Masayoshi Oikawa, Joerg Herrmann

Antioxid Redox Signal· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Downregulation of LATS1/2 Drives Endothelial Senescence-Associated Stemness (SAS) and Atherothrombotic Lesion Formation.
Sivareddy Kotla, Jonghae Lee, Kyung Ae Ko, Weiqing Chen, Venkata Subrahmanya Kumar Samanthapudi, Joerg Herrmann

bioRxiv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Independent and Incremental Value of ECG Markers for Prediction of Cancer Therapy-Related Cardiac Dysfunction.
Ishmam Ibtida, Xiaoyue Ma, Mohammed Al-Sadawi, Ioanna Kosmidou, Joerg Herrmann

J Am Heart Assoc· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advance at a glance: contributions to cardio-oncology.
Joerg Herrmann

Eur Heart J Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The year in cardiovascular medicine 2024: the top 10 papers in cardio-oncology.
Joerg Herrmann, Teresa López-Fernández, Alexander R Lyon

Eur Heart J· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New insights into therapeutic strategies, drugs, and targets for advancing cancer therapy-related cardiovascular toxicity.
Yong Wang, Weili Li, Chun Li, Tingting Zhou, Joerg Herrmann

Sci Bull (Beijing)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality-of-Care Measures for Cardio-Oncology: An IC-OS and ACC Cardio-Oncology Leadership Council Perspective.
Vijay U Rao, Anita Deswal, Daniel Lenihan, Susan Dent, Teresa Lopez-Fernandez, Joerg Herrmann

JACC CardioOncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and Predictors of Severity of Immunotherapy-Related Myocarditis.
Dame Idossa, Joerg Herrmann, Kathryn J Ruddy

JACC CardioOncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the diagnostic and prognostic value of criteria for immune checkpoint inhibitor related myocarditis.
Milagros Pereyra Pietri, Juan M Farina, Isabel G Scalia, Ahmed K Mahmoud, Michael Roarke, Joerg Herrmann

Cardiooncology· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer.
Marc P Bonaca, Ninian N Lang, Alice Chen, Laleh Amiri-Kordestani, Leslie Lipka, Joerg Herrmann

JACC CardioOncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence and Expert Panel Recommendations.
Anne Blaes, Anju Nohria, Saro Armenian, Carmen Bergom, Paaladinesh Thavendiranathan, Joerg Herrmann

JACC CardioOncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis